Skip to content

A preliminary study of the effects of episil(R) oral liquid on chemotherapy- and/or radiation-induced oral mucositis

A preliminary study of the effects of episil(R) oral liquid on chemotherapy- and/or radiation-induced oral mucositis - A preliminary study of episil(R) oral liquid

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000029244
Enrollment
10
Registered
2017-09-26
Start date
2017-11-21
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chemotherapy- and/or radiation-induced oral mucositis

Interventions

Sponsors

Okayama University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Patients aged 20 years or over of age at the date of obtaining informed consent 2) Patients who are suffering from oral mucositis due to chemotherapy and/or radiotherapy or conditioning regimens prior to a hematopoietic stem cell transplantation 3) Patients who are suffering from pain inside the oral cavity caused by oral mucositis, and pain assessment by Universal Pain Assessment Tool results in at least 5 of Likert scale (0~10) at the start of application of episil(R) 4) Patients at good performance status; eg., at Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, 2 and 3

Exclusion criteria

Exclusion criteria: 1) Patients have tumor region inside oral cavity 2) Patients have severely injured area not due to oral mucositis 3) Patients who are known or suspected CNS tumor, metastasis or invasion to the CNS 4) Patients have started the rescue medications on Day 1 prior to the application of episil(R) 5) Patients have known allergy to any ingredient in episil(R) 6) Patients who are participating in other clinical trials 7) Female patients who are breast-feeding, pregnancy or planned pregnancy 8) Patients with considerable concern for compliance with the protocol, in the judgment of investigator

Design outcomes

Primary

MeasureTime frame
Change in the pain intensity in the oral cavity during 2 hours after a single application of episil(R), assessed by numerical rating scale score

Secondary

MeasureTime frame
Feeling of application of episil(R), use of rescue mediation, and the incidence of adverse events and device deficiencies

Countries

Japan

Contacts

Public ContactYoshihiko Soga

Okayama University Hospital Division of Hospital Dentistry

y_soga@okayama-u.ac.jp+81-86-235-6588

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026